Pertinent market/industry news/articles, page-1775

First 1775 Last

Share
Profile

Follow
Olipapa88

390 Posts.

496

15/06/19

09:28

Post #: 39072220
Share

Originally posted by Sally_Will: ↑

Hi Ollpapa88,

I am not sure to which options you refer but if you mean the free shares in the proposed spin out of Ardea then following on from several previous similar Ian Buchhorn involvements in spin out's when he was at Heron Resources, then it is very likely the new shares will be .20 cent fully paid shares and NOT options.

I am aware of several European residents who in the past STILL received their entitlement even though the prospectus said Australian residents only or similar. This happened for them on each occasion of a spin out.

I think that it depends on how they or you purchased these shares in the first instance as it appears these people purchased through their bank and the banks held their shares IN THE FORM OF Shareholding Statements.

To be 100% assured maybe you could alter your address to an Australian address (maybe a friend?) as that way your friend would receive the prospectus as well, although I dare say the prospectus and application form for additional shares will also be available on line in the form of an announcement by Ardea however the personalised application form to a "priority purchase" of additional shares (over and above your free entitlement) might need an Australian address.

Maybe you should speak to whoever you bought your shares thru and ask them if they are likely to receive information in the form of a prospectus or application form or any correspondence from the company (Ardea) would they in turn contact or advise you?

Also ask them if you can change your address to an Australian address.

I hope you can understand what I am trying to say.

Better be safe than sorry and act on this now rather than when the spin out occurs.

Good luck.

Expand

Very helpfull! I bought my shares trough interactivebrookers. I am an EU citizen,so maybe my chances are good, about the australian address i dont think i have a shoot

ARL Price at posting: 39.0¢ Sentiment: Buy Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

There are more pages in this discussion • 3,889 more messages in this thread...

First 1775 Last

Add ARL (ASX) to my watchlist

(20min delay)
Last 39.0¢		Change 0.015(4.00%)		Mkt cap ! $77.87M

Open	High	Low	Value	Volume
39.0¢	39.5¢	39.0¢	$4.107K	10.53K

Buyers (Bids)

No.	Vol.	Price($)
1	317	39.5¢

Sellers (Offers)

Price($)	Vol.	No.
40.0¢	1729	1

View Market Depth

No.	Vol.	Price($)
1	317	0.395
2	55048	0.390
2	2624	0.385
3	10159	0.380
2	15686	0.375

Price($)	Vol.	No.
0.400	1729	1
0.415	3420	1
0.420	14800	2
0.425	3760	1
0.430	3255	1

Last trade - 12.02pm 07/10/2024 (20 minute delay)

ARL (ASX) Chart

Pertinent market/industry news/articles, page-1775

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Pertinent market/industry news/articles, page-1775

Top Stories

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News